TerminatedPhase 2

A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

United States296 participantsStarted 2013-01

Plain-language summary

To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.

Who can participate

Age range50 Years – 95 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Complete Week 12 visit of AG201 * Both patient and study partner/caregiver are willing and able to participate in all scheduled evaluations and complete all required tests Exclusion Criteria: * Is currently using any other investigational or experimental drugs or devices * Has significant worsening of medical conditions or dementia such that it may preclude completion of this safety extension study

What they're measuring

Number of Participants Experiencing Treatment Emergent Adverse Events

Timeframe: 36 weeks

Trial details

NCT IDNCT01766336

SponsorOPKO Health, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-08

Results submitted2016-04-07

View on ClinicalTrials.gov More Alzheimer's Disease trials